TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30062946
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of TXA followed by 1.0 g orally three, nine, and 15 hours postoperatively (group D)
Study: 26230270
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day desvenlafaxine
Study: 26230270
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day desvenlafaxine
Study: 18413835
Drug: Doxercalciferol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxercalciferol (10 microg orally, days 1-28) with docetaxel (35 mg/m2 i.v., days 1, 8, and 15)
Study: 18413835
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with docetaxel (35 mg/m2 i.v., days 1, 8, and 15)
Study: 12950597
Drug: 3'SL 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3'SL 10 g/day
Study: 12950597
Drug: 3'SL 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3'SL 20 g/day
Study: 7572258
Drug: Moclobemide (MOC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (MOC; maximum dose 600 mg)
Study: 7572258
Drug: Doxepin (DOX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (DOX; maximum dose 250 mg)
Study: 7036171
Drug: Pulses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulses of methylprednisolone, immunosuppressive drugs and anticoagulants plus plasma exchanges for one to two months (PE+)
Study: 7036171
Drug: Pulses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulses of methylprednisolone, immunosuppressive drugs and anticoagulants (Control)
Study: 30549127
Drug: Carbamazepine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (single oral dose)
Study: 30549127
Drug: Brivaracetam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (single oral dose)
Study: 30549127
Drug: Tiagabine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (single oral dose)
Study: 26087567
Drug: Jintian'ge capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintian'ge capsule in addition to percutaneous kyphoplasty (PKP)
Study: 23579320
Drug: Control conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control conditions (acetaminophen and placebo)
Study: 22384545
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection (DHI) 20 mL intravenously dripped in 250 mL 0.9% sodium chloride injection from 2-3 days before PCI to 3 days after PCI, once daily.
Study: 22384545
Drug: Routine medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine medicines including loperamide injection, enteric coated aspirin, Betaloc, and routine rehydration therapy (Control group).
Study: 19455042
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at target plasma concentrations (0, 1.3, 1.7, 2.0, 2.4, 2.8 microg ml(‐1))
Study: 16963215
Drug: Daily cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cannabis users (N=18)
Study: 16963215
Drug: Non-daily cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-daily cannabis users (N=20)
Study: 11168270
Drug: Implant-mucosa-borne overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-mucosa-borne overdenture on 2 IMZ implants (IMZ-group)
Study: 11168270
Drug: Mainly implant-borne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly implant-borne overdenture retained by a transmandibular implant (TMI-group)
Study: 9923572
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ASA plain
Study: 9923572
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ASA enteric-coated
Study: 9923572
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ASA plain
Study: 2748718
Drug: Two cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycle ergometer exercise sessions and one bronchial hygiene treatment session per day (EX Group)
Study: 2748718
Drug: Three bronchial
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three bronchial hygiene treatment sessions per day (PD Group)
Study: 25453519
Drug: Therapeutic yoga
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic yoga (16 sessions, twice a week for 8 weeks)
Study: 18829015
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human FSH plus hCG after GnRH agonist treatment
Study: 17697815
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (aspirin, clopidogrel, and cilostazol)
Study: 15530674
Drug: HB‐AS04 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS04 (2 doses at 0 and 6 months)
Study: 15530674
Drug: Comparator vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator vaccine (3 doses at 0, 1, and 6 months)
Study: 11586161
Drug: Low-intensity pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pulsed ultrasound therapy (20-minute daily applications at the site of the nonunion)
Study: 7924650
Drug: Retinamide II
Normalized name: retinamide
DrugBank: Retinamidic acid (DB17418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinamide II (RII) suppository intravaginally, once daily for 50 days
Study: 7924650
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily for 50 days
Study: 4877801
Drug: Micronized flumedroxone
Normalized name: flumedroxone
DrugBank: Flumedroxone (DB13610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized flumedroxone 10 mg t.d.s.
Study: 28195931
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication adherence
Study: 26865198
Drug: Poor medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor medication adherence
Study: 21947753
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 50 mg/kg bolus followed by 15 mg/kg/h infusion and another 50 mg/kg into the bypass circuit
Study: 18649974
Drug: Intravenous glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glutamine dipeptide
Study: 16824141
Drug: MPA pharmacokinetics
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA pharmacokinetics with tacrolimus
Study: 9293933
Drug: Butyric acid
Normalized name: butyric acid
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyric acid enemas (40 mmol) twice per day for two weeks
Study: 7994793
Drug: Single instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single instillation of hydroxypropylcellulose-doxorubicin (20 mg/20 ml)
Study: 3176836
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 0.5 mg/kg midazolam and 0.05 mg/kg atropine
Study: 3176836
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 0.15 mg/kg midazolam and 0.02 mg/kg atropine
Study: 24109189
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg + HCTZ 25 mg
Study: 24109189
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg + HCTZ 25 mg
Study: 22074958
Drug: Chlorpromazine 100
Normalized name: chlorpromazine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 100 mg simple dose formulation
Study: 18202711
Drug: Oblique injection
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblique injection technique
Study: 14606135
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with factor V Leiden mutation
Study: 10678615
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (2,000 microg daily)
Study: 7687608
Drug: Histamine challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine challenge (1 mg)
Study: 7687608
Drug: Allergen challenge
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen challenge (increasing doses)
Study: 3307584
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human insulin (0.2 U/kg body weight)
Study: 3307584
Drug: Purified pork
Normalized name: Insulin purified pork
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purified pork insulin (0.2 U/kg body weight)
Study: 2870943
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human insulin
Study: 30403574
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg subcutaneously every 2 weeks)
Study: 26981608
Drug: Comprehensive oral
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive oral health care (oral health examination, oral health education, topical fluoride application, dental treatment)
Study: 26981608
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral health examination only)
Study: 20580423
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg) and Vitamin E (400 IU) daily until delivery
Study: 18648200
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) treatment, mean dose 158 mg, duration at least 3 months
Study: 18648200
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) treatment
Study: 11005755
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of lidocaine
Study: 1832607
Drug: Picotamide monohydrate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide monohydrate, 1200 mg daily three days before surgery, tapering to 900 mg daily postoperatively
Study: 30249195
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (300 mg)
Study: 27259709
Drug: EP217609 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP217609 (1, 3, or 10 mg)
Study: 16392983
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and interpersonal psychotherapy
Study: 1975780
Drug: Nisoldipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (2 X 10 mg)
Study: 1975780
Drug: Captopril (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (3 X 25 mg)
Study: 27984226
Drug: Lidocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (20 mL 2% lidocaine with epinephrine)
Study: 21273491
Drug: Insulin requirements
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin requirements during high altitude trekking
Study: 21273491
Drug: Insulin doses
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin doses at altitudes >5,000 m
Study: 19190034
Drug: Brief supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief supportive therapy
Study: 17080587
Drug: Transdermal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal continuous hormone replacement therapy (HRT) with estradiol 50 microg/day and norethisterone acetate 140 microg/day (Estalis)
Study: 17080587
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy (HRT) with estradiol 2 mg and norethisterone acetate 1 mg (Kliogest)
Study: 14769753
Drug: Nebulized opioids
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized opioids (morphine, hydromorphone)
Study: 11443567
Drug: Endotoxin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin and ibuprofen
Study: 11443567
Drug: Soluble tumor
Normalized name: SOLUBLE TUMOR NECROSIS FACTOR (1-METHIONINE,31-CYSTEINE,69-VALINE,87-HISTIDINE,101-ALANINE,145-ARGININE) (HUMAN CONSTRUCT XPRO1595), 31-THIOETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYL)-.OMEGA.-METHOXYPOLY(OXY-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble tumor necrosis factor receptor
Study: 11443567
Drug: Soluble interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble interleukin-1 receptor
Study: 2958817
Drug: Depilatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depilatory agent (group II)
Study: 29669668
Drug: MF-sponsor (mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF-sponsor (mometasone 50 μg)
Study: 29669668
Drug: MF (mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF (mometasone 50 μg)
Study: 26198280
Drug: 20 G
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G vitrectomy and circumferential scleral buckling (E1)
Study: 26198280
Drug: 20 G
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G vitrectomy alone (C)
Study: 26198280
Drug: 23/25 G
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23/25 G vitrectomy alone (E2)
Study: 22509949
Drug: Tiotropium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium treatment
Study: 21120304
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (5 joule/cm² at each point over maximum 5‐6 painful points for 1 minute)
Study: 18341614
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + Interferon (IFN)-beta
Study: 16449522
Drug: 6-methylprednisolone (6MPred)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-methylprednisolone (6MPred) 2 mg/kg per day for 5 consecutive days
Study: 16449522
Drug: 6MPred 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MPred 5 mg/kg per day for 10 days
Study: 16449522
Drug: 6MPred 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6MPred 5 mg/kg per day for 10 days + rabbit anti-thymocyte globulin (ATG, 6.25 mg/kg in 10 days)
Study: 15804077
Drug: Sub-conjunctiva injection
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-conjunctiva injection of dexamethasone combined with eye drops of 1% CsA and 0.1% dexamethasone
Study: 9823729
Drug: 0.5% KTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% KTP gel
Study: 9823729
Drug: 1.0% KTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% KTP gel
Study: 9823729
Drug: 1.0% KTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% KTP alternate gel
Study: 9823729
Drug: 2.0% KTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% KTP gel
Study: 9823729
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg KTP capsule (positive control)
Study: 8911891
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin (twice‐weekly intramuscular injections for 5 weeks; total dose 2500 IU for patients less than 1‐year‐old, 5000 IU for 1‐ to 6‐year‐olds, 10000 IU for 6‐ to 11‐year‐olds)
Study: 1529280
Drug: Cisapride, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 10 mg three times daily for 14 days
Study: 6732212
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg once a day for 5 days)
Study: 6732212
Drug: Bacitracin ointment
Normalized name: Bacitracin Ointment
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bacitracin ointment (topically applied three times a day for 10 days)
Study: 29764875
Drug: High-dose GHX02
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GHX02 (1920 mg/day)
Study: 29764875
Drug: Standard-dose GHX02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose GHX02 (960 mg/day)
Study: 30925824
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran supplement containing PRB (43 μg LRA/day)
Study: 23059159
Drug: BL-1020 20-30
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-1020 20-30 mg/d
Study: 23059159
Drug: Risperidone (2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2-8 mg/d)
Study: 23059159
Drug: BL-1020 10
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-1020 10 mg/d
Study: 16055579
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.125% bupivacaine with 2 microg/mL fentanyl at a rate of 8 mL/h (group A)
Study: 16055579
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus of 10 mL of 0.25% bupivacaine on demand (group B)
Study: 1833042
Drug: Cisplatin, high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, high-dose cytosine arabinoside, and caffeine (CAC)
Study: 6120313
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral immunisation with cholera B subunit
Study: 6120313
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular immunisation with cholera B subunit
Study: 6120313
Drug: Second immunisation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second immunisation by either route (oral or intramuscular)
Study: 30638065
Drug: CBT-plus-fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-plus-fluoxetine
Study: 26804640
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 25 mg of cinacalcet
Study: 26804640
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 50 mg of cinacalcet
Study: 26804640
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 100 mg of cinacalcet
Study: 26804640
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 50 mg of cinacalcet once daily for 7 days
Study: 26804640
Drug: Cinacalcet administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet administration (single and multiple doses)
Study: 22353201
Drug: S-1 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 at 25 mg twice daily for 5 days (level 1)
Study: 22353201
Drug: S-1 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 at 40 mg twice daily for 5 days (level 2)
Study: 17393237
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide and formoterol
Study: 3289861
Drug: Topical hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hyperbaric oxygen (THO) treatment for 2 weeks
Study: 3289861
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no THO treatment)
Study: 26244877
Drug: ADT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT plus docetaxel (75 mg/m² every 3 weeks for six cycles)
Study: 24195207
Drug: Acupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture + medication (SSRIs)
Study: 24195207
Drug: Medication (SSRIs)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (SSRIs)
Study: 19321522
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (participated in two weeks of daily training on weekdays)
Study: 10516943
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir sulfate 400 mg orally every 6 hours with placebo
Study: 10516943
Drug: TMP 160
Normalized name: SMX 800 MG / TMP 160 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP 160 mg/SMZ 800 mg orally every 12 hours with placebo
Study: 7586112
Drug: Succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1 mg.kg‐1 (SxCh)
Study: 7586112
Drug: Vecuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.3 mg.kg‐1 (Vec 0.3)
Study: 7586112
Drug: Vecuronium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.5 mg.kg‐1 (Vec 0.5)
Study: 7586112
Drug: Vecuronium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.5 mg.kg‐1 (Vec 0.5) in beta blocker group
Study: 2149512
Drug: Isradipine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5-10 mg bid)
Study: 2149512
Drug: Prazosin (2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2-8 mg bid)
Study: 30280946
Drug: CE/BZA doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/BZA doses and Placebo
Study: 25138548
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers in induced sputum (MMP-9 and TIMP-1)
Study: 22743565
Drug: Erythropoietin analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin analog treatment
Study: 8596815
Drug: ProSol PDS
Normalized name: Prosol
DrugBank: Proline (DB00172)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ProSol PDS 22‐4 (irrigating solution)